Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;34(3):342-346.
doi: 10.1007/s12291-018-0749-7. Epub 2018 Mar 21.

Irisin and Visfatin Predicts Severity of Diabetic Nephropathy

Ramalingam Mageswari  1 , M G Sridhar  1 , H Nandeesha  1 , Sreejith Parameshwaran  1 , K V Vinod  1
Affiliations
Free PMC article

Irisin and Visfatin Predicts Severity of Diabetic Nephropathy

Ramalingam Mageswari et al. Indian J Clin Biochem. 2019 Jul.
Free PMC article

Abstract

Although the roles of irisin and visfatin have been well established in diabetes mellitus, there are limited studies about their association in diabetic nephropathy. The present study was designed to assess the levels of irisin and visfatin and their association with the severity of diabetic nephropathy. 43 diabetic nephropathy cases and 43 diabetic subjects without nephropathy were enrolled in the study. Serum levels of irisin and visfatin were compared in both the groups. Irisin and visfatin were significantly increased in diabetic nephropathy cases when compared with diabetes subjects without nephropathy. eGFR was negatively correlated with visfatin (r = -0.323, p = 0.034), irisin (r = -0.324, p = 0.034), urine albumin (r = -0.443, p = 0.003) and albumin creatinine ratio (r = -0.419, p = 0.005) in patients with diabetic nephropathy. Visfatin was significantly elevated in stage IV nephropathy compared with stage III nephropathy. We conclude that irisin and visfatin are elevated in diabetic nephropathy and can be an index of its severity.

Keywords: Adiponectin; Diabetes mellitus; Irisin; Nephropathy; Visfatin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–176. doi: 10.2337/diacare.28.1.164. - DOI - PubMed
    1. Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy—a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc. 2004;96(11):1445. - PMC - PubMed
    1. Unnikrishnan R, Rema M, Pradeepa R, Deepa M, Shanthirani CS, Deepa R, et al. Prevalence and risk factors of diabetic nephropathy in an urban South Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45) Diabetes Care. 2007;30(8):2019–2024. doi: 10.2337/dc06-2554. - DOI - PubMed
    1. Gurel A, Atli H, Duzenci D, Aydin S, Dogukan A. Plasma and saliva irisin levels of patients with diabetic nephropathy and non-diabetic proteinuria. Turk Nephrol Dial Transplant. 2015;24(3):302–306. doi: 10.5262/tndt.2015.1003.09. - DOI
    1. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013;98:769–778. doi: 10.1210/jc.2012-2749. - DOI - PubMed

LinkOut - more resources